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Abstract
Background: Laryngopharyngeal reflux is a prevalent, not well-understood disease affecting a high proportion of
patients who seek laryngology consultation. The objective of this prospective case series is to explore the subjective
and objective voice modifications in Laryngopharyngeal reflux (LPR), especially the usefulness of acoustic
parameters as treatment outcomes, and to better understand the pathophysiological mechanisms underlying the
development of voice disorder.
Methods: Forty-one patients with a reflux finding score (RFS) > 7 and a reflux symptom index (RSI) > 13 were
enrolled and treated with pantoprazole 20 mg twice daily for three months. RSI, RFS, Voice Handicap Index (VHI),
and Grade, Roughness, Breathiness, Asthenia, Strain and Instability (GRBASI) were assessed at baseline and after
three months post-therapy. Acoustic parameters were measured by selecting the most stable interval of the vowel
/a/. A study of correlations between acoustic measurements and laryngoscopic signs was conducted in patients
with roughness. Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS).
Results: Significant improvement in RSI, RFS, VHI, jitter, percent jitter, relative average perturbation (RAP),
shimmer, percent shimmer, and amplitude perturbation quotient (APQ) was found at 3 months of treatment
(p < .05). A correlation analysis revealed significant correlations between the grade of dysphonia, breathiness,
asthenia, instability and jitter, percent jitter, RAP, shimmer, percent shimmer and APQ. In dividing our cohort
into two groups of patients according to the presence of roughness, shimmer, percent shimmer and APQ
significantly improved in patients with roughness, but no positive correlation was found between acoustic
parameters and laryngoscopic signs.
Conclusion: Acoustic parameters can help to better understand voice disorders in LPR and can be used as
treatment outcomes in patients with roughness.
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Background
Laryngopharyngeal reflux (LPR) is the back flow of
gastric contents into the laryngopharynx where it
comes in contact with the tissues of the upper aerodi-
gestive tract [1]. It concerns 4 to 10 % of patients who
seek Ear Nose Throat (ENT) consultation and 1 % of
patients in primary care practice [2–4]. The most
common symptoms reported are globus sensation
(88 %), throat clearing (82 %), and voice disorders such
as hoarseness (79 %) [5, 6]. Heartburn accounts for
less than 40 % of cases, whereas esophagitis concerns
only 25 % of LPR patients [7, 8]. The major etiologic
factor for hoarseness of more than 3 months duration
is LPR, with a prevalence of 55 to 79 % in hoarse pa-
tients [9–11]. In comparison with healthy subjects,
LPR patients often reported abnormal subjective voice
characteristics such as musculoskeletal tension, hard
glottal attack, glottal fry, vocal forcing, forcing sensa-
tions, clamping, vocal fatigue, prolonged voice warm-
up time, and restricted tone placement [12–14]. LPR
signs include posterior commissure hypertrophy
(89 %), vocal fold edema (79 %), hyperemia (79 %), and
diffuse laryngeal edema (76 %)5. This clinical entity
considerably affects patients’ quality of life by reducing
the speaker’s communicative effectiveness [2, 15].
Specifically, LPR is related to 50 to 78 % of the popula-
tion with voice complaints and 91 % of voice disorders
in the elderly [16–18]. Based on these voice disorders,
many authors have used acoustic parameters as out-
comes of medical treatment efficacy in LPR patients or
in LPR patients with hoarseness, but results are mixed
and controversial among studies [19–21]. Undoubt-
edly, some observe improvements of some acoustic
parameters values [20, 21], and others refute these
results [22, 23]. These varied results do not help the
understanding of the pathophysiological mechanisms
underlying hoarseness in LPR patients. Specifically,
some authors suggested that vocal fold edema may be
the main sign responsible for irregular vocal fold
vibration leading to hoarseness [13], whereas other
suspected mechanisms include dryness, keratosis,
thickening of the epithelium, ulcerative lesions and
alterations of the Reinke space [24].
LPR disease has been the subject of several case-
control studies, which have concluded that a signifi-
cantly lower voice quality (subjective and objective
assessments) in LPR patients compared to controls [25].
The aim of this study is i) to explore the subjective
and objective voice evolutions in LPR disease (LPRD),
ii) to assess the usefulness of acoustic parameters as
treatment outcomes in the general and rough LPR
populations, and iii) to better understand the patho-
physiological mechanisms underlying the development
of voice disorder.
Methods
Forty-one adult outpatients who visited the ENT out-
patient department of the Epicura Hospital (Belgium)
with LPR-related symptoms (hoarseness, throat clearing,
cough, globus pharyngeus, dysphagia, throat pain, excess
throat mucus or postnasal drip, heartburn, etc.) since
minimum 3 months were studied prospectively from Sep-
tember 2013 to March 2015. LPR diagnosis was per-
formed by French versions of reflux symptom index (RSI)
and reflux finding score (RFS), both initially developed by
Belafsky et al. [26]. Indeed, even if the utilization of pH
metry remains controversial, these authors have dem-
onstrated that these thresholds (RSI > 13 and RFS > 7)
were highly correlated with pathological pH monitoring
(pH < 4) [26]. To be eligible as LPR patients in our
study, patients must have presented an RSI score > 13
and an RFS score > 7. A physician (who did not know
the results of the RSI) assessed the RFS score in a blind
manner at baseline and after treatment. Patients were
excluded if they met the following criteria: vocal over-
use, neurological disease affecting voice, psychiatric
illness, upper respiratory tract infections within the last
month, an antacid treatment already started (i.e.,
proton pump inhibitor(s) (PPI(s)), gastroprokinetic, or
antihistamine), previous history of cervical surgery or
radiotherapy, laryngeal trauma, vocal cord paralysis/
paresis, benign vocal fold lesions, pharyngolaryngeal
malignancy, seasonal allergies, PPI hypersensitivity,
untreated thyroid disease, prior antireflux surgery, or
chemical exposure causing laryngitis. Moreover, active
smokers, alcoholics and pregnant and lactating women
were also excluded.
The study protocol was approved by the local ethical
committee of the Epicura Hospital (n° A2014/001). After
obtaining informed consent from each patient, they were
treated with diet and lifestyle measures and twice-daily
proton pump inhibitors (20 mg pantoprazole). Patients
did not receive vocal hygiene teaching and they had not
consulted a speech therapist. Both the patient and the
physician have evaluated the respect of the diet advices
after the treatment period using a scale ranging from 0
(recommendations not respected) to 10 (recommenda-
tions fully respected). At baseline and after 3 months of
treatment, subjects completed questionnaires (RSI and
voice handicap index (VHI)) and underwent videolaryn-
gostroboscopy (RFS; StrobeLED - CLL-S1, Olympus Cor-
poration, Hamburg, Germany) and voice recording by the
same practitioner (JL). Among the perceptual voice items
assessed by Grade, Roughness, Breathiness, Asthenia,
Strain, Instability (GRBASI) score, roughness is often the
most prevalent perceptual voice characteristic in LPR
patients (without vocal abuse, etc.) [25]. At baseline, the
main clinician (JL) performed a subjective evaluation of
the perceptual roughness of the patients using GRBASI
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scale to classify the patients into two groups following the
severity of the perceptual roughness: “patients without
roughness” (absence or mild grade) and “patients with
roughness” (moderate or severe grade). Moreover, an
experienced physician performed the blinded assessment
of the patient perceptual voice quality (with GRBASI) on
the basis of the recordings. The physician did not know
the time of the recording (pre and post-therapy). In regard
to the voice analysis, subjects were instructed to produce
the vowel /a/ three times, at modal phonation, for a time
corresponding to the maximum phonation time to
optimize the research of the most stable interval. Voice
assessments were conducted in a sound-treated room
with a high-quality microphone (Sony PCM-D50; New
York, NY, USA) placed at a distance of 30 cm from the
patient’s mouth. We treated the speech signal using
MDVP® software (KayPentax®, Paragon Drive Montvale,
NJ, USA) to measure Jitter percent (Jitt), Relative Average
Perturbation (RAP), Pitch Perturbation Quotient (PPQ),
Fundamental frequency variation (vF0), Shimmer percent
(Shim), Amplitude Perturbation Quotient (APQ), Peak-to-
Peak Amplitude Variation (vAm), and Noise Harmonic
Ratio (NHR). Even if some acoustic parameters may be
correlated, we made the choice to keep all parameters to
evaluate their sensitivity in the assessment of the treat-
ment effectiveness. The measurement of acoustic values
at an interval of 1 s was considered the most stable by
showing the lowest jitt, shim and NHR values. These mea-
sures were performed in the entire cohort and in patients
with moderate and severe roughness following the phys-
ician assessment (GRBASI) and following the patient (RSI,
first item and VHI total score > 20). An experienced phys-
ician performed a second assessment of GRBASI in a
blind manner for the correlation study. A correlation
study between the respect of treatment, the subcategories
of RSI and RFS, blinded GRBASI items and acoustic
parameters was conducted.
Statistical analysis was performed using the Statistical
Package for the Social Sciences for Windows (SPSS
version 22.0; IBM Corp. Armonk, NY). Changes in RSI,
RFS, VHI, GRBASI scores were calculated using the
Wilcoxon signed-rank test. The effect of treatment on
acoustic parameters was also calculated using Wilcoxon
signed-rank test, whereas correlations between diet
respect, GRBASI, RSI, RFS and acoustic parameters were
calculated using Pearson’s correlation test. A level of
significance of .05 was adopted.
Results
Subject characteristics
From the 54 patients identified as candidates, 41 com-
pleted the study. There were 18 men (44 %) and 23
women (56 %). The mean age of subjects was 50 years
(50 in the female subgroup (24–72), and 51 in the male
subgroup (19–86)). The average body mass index of the
participants was 26.64 kg/m2. There were no adverse
reactions to the treatment. All patients respected the
intake of PPIs. A lot of potential candidates were not
recruited because they already were on PPI(s). The most
common primary complaints concerned cough (N = 8,
19.51 %), globus sensation (N = 7, 17.07 %), odynophagia
(N = 7, 17.07 %), and dysphonia (N = 6, 14.63 %). Other
symptoms were found in less than 10 % of patients.
When we focused on the complaints exhibited by RSI,
throat clearing (N = 38, 92.68 %), dysphonia (N = 37,
90.24 %), mucous sensation/postnasal drip (N = 34,
82.93 %), and chest pain/heartburn/stomach disorder(s)
(N = 33, 80.49 %) were the most prevalent symptoms.
Clinical and subjective voice assessment evolution
In the first part of our study, we subjectively assessed
the voice of our patients suffering from LPR before and
after a three month treatment of pantoprazole (20 mg
twice a day). Our subjective analysis comprised the RSI,
RFS, VHI and GRBASI scores. The mean RSI for the
pretreatment group was 22.98 ± 7.05, which was signifi-
cantly higher than the mean RSI for the posttreatment
group (8.02 ± 5.18) (Table 1). The mean value of RFS
was 10.73 ± 2.24 in the pretreatment group and de-
creased significantly (4.61 ± 3.20) in the posttreatment
group. Therefore, the clinical assessments demonstrated
an important improvement characterized by a significant
decrease in both RSI (p < 0.001) and RFS (p < 0.001) after
12 weeks of treatment (Table 1). Some clinical pictures
of signs of LPR disease are available before and after
treatment in Fig. 1.
Table 1 Pre- and posttreatment clinical and subjective voice
assessments in LPR patients
Scales pretreatment posttreatment Z p-value*
RSI 22.98 ± 7.06 8.02 ± 5.18 −5.52 < 0.001
RFS 10.73 ± 2.24 4.61 ± 3.20 −5.44 < 0.001
VHI 18.07 ± 12.98 9.10 ± 8.93 −4.38 < 0.001
VHIe 3.54 ± 4.06 1.63 ± 2.90 −3.67 < 0.001
VHIp 9.58 ± 6.85 5.34 ± 5.13 −3.86 < 0.001
VHIf 4.90 ± 4.65 5.34 ± 5.13 −4.08 < 0.001
Blinded
Grade 0.83 ± 0.67 0.80 ± 0.56 −0.23 0.819
Roughness 0.88 ± 0.71 0.76 ± 0.58 −1.04 0.297
Breathing 0.61 ± 0.74 0.56 ± 0.59 −0.43 0.670
Asthenia 0.44 ± 0.74 0.39 ± 0.67 −0.29 0.768
Strain 0.93 ± 0.76 0.98 ± 0.69 −0.36 0.721
Instability 0.98 ± 0.79 0.90 ± 0.77 −0.54 0.590
*Wilcoxon matched-pairs signed-ranks test (values and; VHIf Voice Handicap
Index Functional, VHIe Voice Handicap Index Emotional, VHIp Voice Handicap
Index Physic, VHI Voice Handicap Index
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The mean VHI scoring assessed in the pretreatment
group was 18.07 ± 12.98 and decreased significantly to
9.10 ± 8.93 after three months of treatment (p < 0.001). All
subcategories scores (VHI, VHI emotional, VHI physic,
VHI functional) decreased significantly after 3 months of
treatment. According to Wilcoxon matched-pairs signed-
ranks test, the perceptual voice quality of patients signifi-
cantly improved in each GRBASI item after 3 months of
therapy (Table 1). The blinded assessment of GRBASI did
not reveal significant change after treatment.
Acoustic parameters
The acoustic parameters in LPR patients before and after
treatment are described in Table 2. Except PPQ, all
values of the acoustic parameters measuring the short-
term perturbation of the fundamental frequency i.e. Jitt,
and RAP showed a significant improvement after treat-
ment. PFR, the acoustic parameter measuring acoustic
disturbance of F0 did not significantly improve after
treatment. In regard to the acoustic parameters measur-
ing the short-term perturbation of the intensity, Shim
and APQ showed a significant improvement after treat-
ment (Table 2). A study of correlations between RFS and
RSI did not report a relevant correlation. In contrast, the
potential correlations between GRBASI assessment and
acoustic measurement revealed different significant
correlations between the grade of dysphonia, breathi-
ness, asthenia, instability and all relevant acoustic pa-
rameters (Table 3). The perception of strain was also
significantly correlated only with Shim and APQ. The
acoustic parameters of patients’ with/without roughness
before and after treatment are described in Tables 4 and
5. All acoustic parameters did not improve after three
months of treatment in the group of patients without
roughness. In patients with roughness, Shim and APQ
significantly improved after treatment (Table 5). Similar
analyses were conducted in patients divided according to
the presence of a pathological VHI score (VHI > 20) or
Fig. 1 laryngological signs before and after treatment. The videostroboscopy at baseline (a) showed laryngeal and inter-arytenoid redness,
posterior commissure hypertrophy, vocal folds irritation and pharyngolaryngeal edema suggesting laryngopharyngeal reflux disease. These signs
improved after treatment (b)
Table 2 Pre- and posttreatment acoustic parameter assessment in LPR patients (mean ± inter-quartile values)
Acoustic Parameters ULNR♯ pretreatment posttreatment Z p-value*
STD 2.04 3.16 ± 2.38 2.59 ± 1.76 −1.34 0.180
vF0 1.10 1.92 ± 1.05 1.59 ± 0.92 −1.19 0.236
Jitt 0.61 1.42 ± 1.10 1.12 ± 1.10 −2.08 0.038
RAP 0.36 0.84 ± 0.65 0.67 ± 0.55 −2.01 0.044
PPQ 0.35 0.84 ± 0.66 0.68 ± 0.52 −1.94 0.053
PFR 2.17 3.10 ± 2.00 2.66 ± 1.00 −1.72 0.084
Shim 2.26 5.14 ± 2.90 4.12 ± 2.30 −2.73 0.006
APQ 1.69 4.35 ± 2.20 3.31 ± 1.82 −3.00 0.003
vAm 9.23 13.75 ± 9.60 13.30 ± 6.58 −0.84 0.403
NHR 0.12 0.14 ± 0.40 0.13 ± 0.03 −0.33 0.741
*Wilcoxon matched-pairs signed-ranks test. ULNR: Upper Limit of N Range, ♯ = based on the MDVP® norms
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the presence of voice disorder (RSI, first item), but few
significant differences were found between the groups.
In regard to potential correlations between the laryngo-
scopic signs (RFS), clinical symptoms (RSI) and acoustic
parameters in rough patients, we did not find significant
correlations between the main laryngoscopic signs, clin-
ical symptoms and acoustic parameters. According to
the Pearson correlation test, we found significant correl-
ation between the respect of diet advices and the im-
provement of RSI score (z = -.420; p = .006).
Discussion
Laryngopharyngeal reflux is a common disease that has
been known as leading to chronic laryngitis and dyspho-
nia. During the past two decades, a few studies have inves-
tigated the pathophysiological mechanisms underlying the
development of LPR signs and symptoms, diagnosis,
medical and surgical treatments. Although poorly and in-
accurately documented and frequently observed by practi-
tioners, voice disorders seem to be prevalent and may be
disabling for patients. Thus, several case-control studies
were conducted demonstrating significant differences in
LPR patients concerning subjective (dysphonia and VHI)
and objective (aerodynamic and acoustic) voice assess-
ments in comparison with healthy subjects [25]. Given the
limitations of the pH monitoring, Belafsky et al. developed
RSI and RFS for both the diagnosis and follow-up of LPR
signs and symptoms [16, 26]. These two scales are readily
administered, highly reproducible, and exhibit excellent
construct- and criterion-based validity [27]. We found that
RSI and RFS improved significantly after 12 weeks of PPIs
and diet behavioral changes. These findings are in accord-
ance with previous studies that observed the decrease in
RSI and RFS after PPI and diet treatment [20, 28–30].
Moreover, we observed a significant correlation between
the respect of the diet advices and the improvement of the
RSI score. This interesting finding strengthens the in-
volvement of the respect of the diet in the enhancement
of the clinical complaints. In contrast, we did not observe
significant improvement of laryngoscopic signs, suspecting
a kind of potential suggestion’s effect of the respect of the
regimen on the symptoms improvement. We did not use
pH metry given the many limitations. Firstly, it is well
known that intermittent reflux may not occur during the
Table 3 Coefficient of correlation (coefficient and p-value) between voice subjective assessment (blinded GRBASI) and acoustic
parameters
G p-value R p-value B p-value A p-value S p-value I p-value
Jitt 0.463 0.002 0.184 0.249 0.548 <0.001 0.505 0.001 0.295 0.061 0.430 0.005
RAP 0.454 0.003 0.190 0.234 0.530 <0.001 0.498 0.001 0.276 0.081 0.419 0.007
Shim 0.500 0.001 0.130 0.416 0.522 <0.001 0.397 0.010 0.417 0.007 0.365 0.019
APQ 0.494 0.001 0.159 0.320 0.463 0.002 0.405 0.009 0.438 0.004 0.401 0.009
The statistical analysis was provided using Pearson's correlation test; Grade (G), Roughness (R), Breathiness (B), Asthenia (A), Strain (S), Instability (I), Jitter percent
(Jitt), Relative Average Perturbation (RAP), Shimmer percent (Shim), and Amplitude Perturbation Quotient (APQ)
Table 4 Pre- and posttreatment acoustic parameters
assessment in LPR patient groups (patients with roughness vs.
patients without roughness; mean and inter-quartile values)
Patients without roughness (n = 26)
A. Parameters ULNR♯ pretreatment posttreatment Z p-value*
STD 2.04 2.70 ± 1.60 2.49 ± 2.47 −0.85 0.395
vF0 1.10 1.69 ± 1.17 1.50 ± 1.18 −0.90 0.367
Jitt 0.61 1.34 ± 1.43 1.19 ± 1.37 −1.46 0.144
RAP 0.36 0.79 ± 0.71 0.71 ± 0.75 −1.26 0.209
PPQ 0.35 0.79 ± 0.65 0.71 ± 0.64 −1.33 0.182
PFR 2.17 2.77 ± 1.50 2.62 ± 1.00 −0.92 0.358
Shim 2.26 4.61 ± 1.92 4.17 ± 2.96 −1.05 0.292
APQ 1.69 3.81 ± 1.53 3.24 ± 2.88 −1.90 0.058
vAm 9.23 12.60 ± 11.93 13.56 ± 9.50 −0.16 0.869
NHR 0.12 0.13 ± 0.04 0.13 ± 0.03 −0.63 0.525
*Wilcoxon matched-pairs signed-ranks test; Acoustic parameters (A. parameters),
Jitter percent (Jitt), Relative Average Perturbation (RAP), Pitch Perturbation
Quotient (PPQ), Fundamental frequency variation (vF0), Shimmer percent
(Shim), Amplitude Perturbation Quotient (APQ), Peak-to-Peak Amplitude
Variation (vAm), and Noise Harmonic Ratio (NHR). ULNR: Upper Limit of N
Range, ♯ = based on the MDVP norms
Table 5 Pre- and posttreatment acoustic parameters
assessment in LPR patient groups (patients with roughness vs.
patients without roughness; mean and inter-quartile values)
Patients with roughness (n = 15)
A. Parameters ULNR♯ pretreatment posttreatment Z p-value*
STD 2.04 3.94 ± 2.14 2.76 ± 1.48 −1.14 0.258
vF0 1.10 2.32 ± 1.13 1.74 ± 0.88 −0.97 0.334
Jitt 0.61 1.60 ± 1.17 1.02 ± 0.75 −1.36 0.173
RAP 0.36 0.92 ± 0.67 0.59 ± 0.50 −1.59 0.112
PPQ 0.35 0.91 ± 0.72 0.61 ± 0.40 −1.36 0.173
PFR 2.17 3.67 ± 2.00 2.73 ± 1.00 −1.48 0.358
Shim 2.26 6.06 ± 4.23 4.03 ± 2.78 −2.78 0.005
APQ 1.69 5.27 ± 3.85 3.44 ± 2.17 −2.33 0.020
vAm 9.23 15.73 ± 8.62 12.84 ± 4.14 −1.02 0.307
NHR 0.12 0.14 ± 0.04 0.13 ± 0.04 −1.25 0.211
*Wilcoxon matched-pairs signed-ranks test; Acoustic parameters (A. parameters),
Jitter percent (Jitt), Relative Average Perturbation (RAP), Pitch Perturbation
Quotient (PPQ), Fundamental frequency variation (vF0), Shimmer percent
(Shim), Amplitude Perturbation Quotient (APQ), Peak-to-Peak Amplitude
Variation (vAm), and Noise Harmonic Ratio (NHR). ULNR: Upper Limit of N
Range, ♯ = based on the MDVP norms
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test period. Thus, 3 episodes per week can be sufficient to
generate LPR disease [31, 32]. These intermittent reflux
episodes often lead to false negatives. Moreover, other
false negatives or false positives may be secondary to the
probe placement, movement or irritation [32]. Secondly,
the normal values for the test could not be definitely
established given the difficulty of carrying out this test in a
large number of normal volunteers. Indeed, it seems that
there would on average of 1.8 episodes per 24 h in healthy
population [33] while another study reported LPR
episodes in 52 % healthy subjects with a cut-off set to 2
episodes per day [34]. Other limitations (i.e., patient resist-
ance, interpretation difficulties, patients rejection, cost,
and equipment availability) limit the utilization of the pH
metry and it is for these reasons that we decided to made
the diagnosis using clinical scales. Among the LPR symp-
toms, many patients report voice disorders notably de-
scribed through the VHI scale in LPRD [13]. In our study,
we used the VHI scale to describe voice complaints and to
indicate treatment efficiency. We found that total and
subcategories of VHI scores significantly improved after
treatment, confirming that VHI is an interesting tool to
assess voice disorders in LPRD. These results corroborate
those of Sereg-Bahar et al., which showed an improve-
ment in VHI after 8 weeks of omeprazole therapy and
dietary advice [35]. Siupsinkiene et al. also reported the
interest to use VHI as an outcome of the efficacy of the
PPI treatment in LPR patients [36]. At the exception of
the study of Park et al., the perceptual voice quality
assessments conducted in LPR studies were not blinded
[13, 37–39]. The study of Park et al. showed a signifi-
cant improvement of all GRBAS items after 3 months
of treatment. These authors defined the significant im-
provement by the enhancement of ≥ 1 item(s) of the
scale, which does not coincide with our statistical
approach, limiting our literature comparison [39]. The
low scores and the lack of significant improvement of
the values of the GRBASI items could be related to a
majority of mild and moderate LPR patient profiles
composing our cohort. Thus, this hypothesis could
highlight the interest for the acoustic measurements to
assess the treatment efficiency. Indeed, it important to
consider that subtle voice changes may be even more
difficult to detect by the usual subjective assessment by
the clinician or the patient him/herself. Therefore,
many studies use various acoustic parameters to study
the pathophysiology or to measure the effectiveness of
treatment. In our study, many acoustic parameters (i.e.,
Jita, Jitt, RAP, Shim, ShdB, and APQ) improved after
treatment in the entire cohort. In their prospective
study, Jin et al. selected the most stable interval with
the lowest jitter value [20]. They found significant
changes in Jitt, Shim, and HNR at 3 months post-
therapy. These findings were corroborated in our study
only in regard to Jitt and Shim. Another study investi-
gating the therapeutic benefit of lansoprazole or omep-
razole plus speech therapy for 8 weeks provided no
significant improvement in any of the acoustic charac-
teristics studied (i.e., Jitt and Shim) [23]. Additionally,
our results reported that acoustic parameters could be
used primarily in rough patients. Indeed, after dividing
our cohort into two patient groups according to the
presence of roughness (assessed by the clinician), we
observed a significant improvement in Shim, ShdB and
APQ only in patients with roughness, and we had 3
more acoustic parameters in the total cohort. The
acoustic parameters measuring the short-term perturb-
ation of the fundamental frequency did not improve
probably because of the reduction of statistical power
due to the lower number of patients in this group.
Shaw et al. showed that all rough patients with sus-
pected LPR at baseline had significant changes in Jitt
and Shim [19], whereas Hamdan found no significant
modification in any of the acoustic parameter values
studied (RAP, Shim, and NHR) after a short period of
4 weeks of PPI treatment [22]. The study by Shaw et al.
reported that the utilization of acoustic measures is im-
portant, especially in rough LPR patients, but is less im-
portant in LPR patients without roughness [19]. Our
results corroborate the fact that the voice quality
(hoarseness, and especially roughness) perceived by the
physician may suggest the utilization of acoustic param-
eters, such as an indicator of the healing of mucosal le-
sions and the treatment efficacy. Nevertheless, our
results should be cautiously compared with the litera-
ture given the myriad of methods used to calculate the
acoustic parameters. Indeed, the results of the acoustic
measurements depend on the software used (and the
algorithms underlying the calculation of acoustic mea-
sures), the type of vowel recorded, the duration of the
analyzed segment, and the method of choice of the
selected interval [25, 40]. Thus, the choice of the most
stable interval of the vocal signal varies among studies.
In our study, we adopted an objective method to select
the most stable 1 s interval by selecting the portion
with the lower values of jitter, shimmer, and NHR that
represents an advantage of this study [41].
To better understand the pathophysiological mecha-
nisms underlying the development of hoarseness, we
conducted a correlation study in rough patients, which
did not show a significant correlation between clinical
symptoms (RSI), laryngoscopic signs (RFS) and acoustic
measurements. These results stand in contrast to the
study by Jin et al., which showed a significant positive
correlation between Jitt and RSI [20]. Other previous
studies did not report a correlation between signs and
symptoms in LPR patients [42]. However, we found
significant correlations between the grade of dysphonia,
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breathiness, asthenia, instability and the values of Jitt,
RAP, Shim, and APQ. Some trials reported similar find-
ings in other vocal diseases [43], but to the best of our
knowledge, no LPR study has previously noted possible
correlations between the values of acoustic parameters
and GRBASI score. Strangely, we did not found the clas-
sical correlations between hoarseness or roughness and
acoustic parameter as found in other diseases. A plaus-
ible explanation can be found by the representation of
the GRBASI components by the experienced physician
who heard a rough and breath voice that he considered,
first and foremost, as breath voice. Similar findings have
already been described [44]. Concerning the lack of cor-
relation between signs and symptoms, several hypoth-
eses can be identified. Firstly, our clinical experience
makes us believe that patients develop their complaints
in various ways. Some patients somatize more than
others for the same complaint leading to differences in
the final value of RSI. Secondly, we also observed in our
clinical practice that some LPR signs causing clinical
symptoms are not described in the RFS scale, such as
hypertrophy of the lingual tonsils and vocal fold kera-
tosis [45]. Regarding the development of roughness,
some studies proposed that the most possible negative
factors altering the periodicity of the vibration cycle and
glottic closure would be slight edema of the vibratory
margin of the vocal cords, which is caused by potentially
noxious materials including gastric acid, pepsin and pan-
creatic enzyme irritation [13]. Other authors proposed
that dryness (sticky laryngeal mucus), keratosis of the
vibratory margin of the vocal folds, thickening of the
epithelium, ulcerative lesions, granulomas and modifica-
tions of the Reinke space would form the basis of the
alteration of the vibratory function of the vocal folds,
especially in mild or moderate LPR patients [46]. Many
of these conditions altering the mechanical and vibration
characteristics of the vocal folds are not described in
RFS and may lead to the development of roughness. In
this study, we did not find a significant correlation be-
tween vocal fold edema, diffuse laryngeal edema, poster-
ior commissure hypertrophy and subjective or objective
voice assessments. Our cohort included a majority of pa-
tients with mild to moderate LPRD without severe signs
of LPR (i.e., polypoid or/and severe vocal fold edema
and/or granulomas) that could also explain our results.
Finally, it is important to consider that genetic differ-
ences between individuals, particularly at the histological
and biomolecular composition of the vocal folds, which
may generate different local reactions to acid irritation
characterized by various responses. Further histological
studies are interesting to explore tissue modifications in
LPR disease to precise some mechanisms. The main
weakness of this study concerns the absence of a
controlled group just treated by diet and behavioral
changes. Indeed, to date, no study was interested to the
impact of the diet vs the impact of the PPI(s) in the
resolution of the voice problems in LPRD. Finally, the
multiple statistical testings of this study were performed
without a Bonferoni correction that may lead to an over-
stated significance.
Conclusion
Our report highlights that changes in diet combined
with pantoprazole twice daily neutralize the acidity
responsible for the inflammation of the upper aerodiges-
tive tract leading to an improvement of laryngeal symp-
toms, signs, perceptual voice disorders, and several
acoustic parameters measuring the short-term perturb-
ation of the fundamental frequency and the intensity,
especially in rough patients. Thus, our correlation analy-
zis showed that the hoarseness (especially roughness) of
the suspected LPR patients could be due to complex
pathophysiological mechanisms and not simply to edema
of the vocal folds such as reported previously [25]. In an
obvious way, the healing of the vocal folds reported in
suspected LPR patients could influence the voice, so that
acoustic parameters would correlate with microscopic
changes not always described in the RFS scale. These
findings support the utilization of acoustic parameters
(using an objective method to determine the most stable
time interval) in the follow-up of LPR patients with
hoarseness and to better understand vocal disorder devel-
opment. Further randomized controlled trials with larger
cohorts and objective acoustic methodological approaches
are needed to confirm the role of each acoustic parameter
in the follow-up of LPRD. Dryness and keratosis of the
vocal folds could be systematically researched in our
laryngological examination and also correlated to objective
parameters.
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